Amgen (FRA:AMG) Tax Expense: €1,102 Mil (TTM As of Mar. 2026)


FRA:AMG Amgen Inc FRA:AMG
86 GF Score
Price €313.55
GF Value €306.82
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Amgen Tax Expense?

Amgen FRA:AMG +0.10% 86 Tax Expense is €1,102 Mil as of Mar. 2026. GuruFocus rates FRA:AMG with a GF Score™ of 86/100 and a GF Value™ of €306.82 (Fairly Valued). The stock has 7 warning signs investors should review.

Amgen's tax expense for the months ended in Mar. 2026 was €229 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2026 was €1,102 Mil.


Amgen  (FRA:AMG) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Amgen Tax Expense Related Terms


Amgen Tax Expense Historical Data

* Premium members only.

The historical data trend for Amgen's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Tax Expense Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 715.08 749.54 1,043.55 495.65 1,080.31

Amgen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 224.78 117.91 600.66 154.57 229.23
FRA:AMG
86GF Score
Amgen Inc FRA:AMG
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,102 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of €1,102 Mil mean?
Amgen (FRA:AMG) has a Tax Expense of €1,102 Mil as of Mar. 2026. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Amgen and its competitors.
Is Amgen's Tax Expense too high?
Amgen's current Tax Expense is €1,102 Mil. Overall, Amgen has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Tax Expense compare to GILD and PFE?
Amgen's Tax Expense of €1,102 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Drug Manufacturers company?
A good Tax Expense depends on the Drug Manufacturers industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Amgen and its competitors. Amgen's current Tax Expense is €1,102 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (FRA:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €306.82, compared to a current price of €313.55 — trading 2.2% above its estimated fair value. The current Tax Expense is €1,102 Mil. Amgen's overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Amgen (FRA:AMG), the current Tax Expense is €1,102 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (FRA:AMG) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of €313.55 is trading 2.2% above its estimated GF Value™ of €306.82. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for FRA:AMG:

  • Tax Expense: €1,102 Mil
  • GF Value™: €306.82 vs. price of €313.55 (2.2% above fair value)
  • GF Score™: 86/100 with 7 warning signs

No single metric tells the full story. See the FRA:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
86GF Score

Get the complete analysis for FRA:AMG

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€313.55
Price
€306.82
GF Value